The abandonment of lasme-cel and eti-cel removes the company's most advanced clinical-stage assets, shifting the entire valuation to preclinical in vivo programs with first human data 12-18 months away. Traders should expect significant volatility as the market re-rates CLLS as a pre-clinical biotech with an uncertain path to revenue. Monitor the September 14 conference call for details on restructuring costs and the extent of headcount reductions.
Price Chart
Executive Summary
Cellectis announced a strategic transformation to become an in vivo gene editing company, advancing two preclinical programs (.HEAL-101 and .HEAL-201) for severe dyslipidemias while exiting its CAR-T cell therapy candidates lasme-cel and eti-cel. The company is realigning operations to extend its cash runway into H2 2028, but the abandonment of its most advanced clinical assets and reliance on early-stage preclinical data introduces significant uncertainty and a negative read-through for the company's near-term value.
Key Facts
- Board approved strategic transformation to in vivo gene editing company on September 11, 2026.
- Advancing .HEAL-101 (APOC3 base editing for severe hypertriglyceridemia) with Phase 1 IIT data planned H2 2027.
- Advancing .HEAL-201 (PCSK9 epigenetic editing for severe hypercholesterolemia) with Phase 1 IIT data planned H1 2028.
- Exiting development of lasme-cel and eti-cel, its two lead CAR-T cell therapy candidates.
- Targeting cash runway extension into H2 2028 through operational realignment and headcount reductions.
- Continuing existing cell therapy partnerships with AstraZeneca, Allogene, Servier, and Iovance.
Financial Impact
No financial figures provided. Cash runway targeted into H2 2028, excluding any potential partnering income from lasme-cel or eti-cel.
Risk Factors
- Preclinical data may not translate to clinical efficacy or safety in humans.
- Phase 1 IITs in China may face regulatory or enrollment delays.
- Cash runway extension depends on successful restructuring and cost savings; potential for further dilution if milestones are missed.
- Competitive landscape for in vivo gene editing and dyslipidemia treatments is rapidly evolving.
- No revenue-generating products; company is entirely dependent on partnerships and capital markets for funding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006010 |
| Document: f6k_091326.htm | 0001171843-26-006010 |
| Document: 0001171843-26-006010-index-headers.html | 0001171843-26-006010 |
| Document: 0001171843-26-006010-index.html | 0001171843-26-006010 |
| Document: 0001171843-26-006010.txt | 0001171843-26-006010 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | 6-K | $1.83 | awaiting T+60 | — | $0.9670 (+47.16%) |
Sep 11, 2026 6w ago | Press Release | $1.83 | awaiting T+60 | — | $0.9670 (−47.16%) |
Aug 6, 2026 11w ago | Press Release | $2.84 | awaiting T+60 | — | $0.9670 (−65.89%) |
Jun 29, 2026 17w ago | Court Ruling | $3.00 $1.43 | ▼ −52.33% | ▼ −55.32% | $0.9670 (−67.77%) |
Jun 25, 2026 17w ago | 6-K | $2.83 $1.51 | ▼ −46.64% | ▼ −52.75% | $0.9670 (−65.83%) |
Jun 25, 2026 17w ago | 6-K | $2.83 $1.51 | ▼ −46.64% | ▼ −52.75% | $0.9670 (−65.83%) |
Jun 11, 2026 19w ago | Press Release | $3.09 $3.24 | ▲ +4.85% | ▲ +0.46% | $0.9670 (−68.71%) |
Jun 9, 2026 19w ago | 6-K | $3.18 $3.32 | ▲ +4.40% | ▼ −2.18% | $0.9670 (−69.59%) |
May 12, 2026 23w ago | 6-K | $3.96 $2.69 | ▼ −32.07% | ▼ −36.45% | $0.9670 (−75.58%) |
May 4, 2026 25w ago | 6-K | $3.76 $2.85 | ▼ −24.20% | ▼ −26.94% | $0.9670 (−74.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers